Functional responses and apoptosis of CD25 (IL-2R alpha)-deficient T cells expressing a transgenic antigen receptor. 1997

L Van Parijs, and A Biuckians, and A Ibragimov, and F W Alt, and D M Willerford, and A K Abbas
Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.

IL-2 was initially defined as a T lymphocyte growth factor, but recent studies have provided evidence that it may also play a role in regulating T cell differentiation, apoptosis, and tolerance. To examine the contribution of IL-2 to these processes, we have bred a class II-restricted TCR transgene into mice deficient in the alpha-chain of the IL-2R, CD25. We show that in response to Ag, T cells from these mice are unable to use IL-2 and, as a result, are less efficient at traversing the cell cycle, and proliferate less than wild-type cells. Furthermore, CD25 -/- T cells exhibit reduced survival in vitro, even in the presence of costimulatory signals. IL-4 and IL-15, a cytokine related to IL-2, enhance the survival and Ag-induced proliferation of CD25 -/- T cells. Activated CD25 -/- T cells are resistant to Fas-mediated activation-induced cell death (AICD), and this defect cannot be corrected by other cytokines. Therefore, IL-2 plays a unique role in regulating AICD, but has redundant roles in T cell survival and proliferation in vitro. The failure of AICD observed with CD25 -/- T cells may explain the unexpected observation that deficiency of IL-2 or of the alpha- or beta-chain of the IL-2R results not in immunodeficiency, but in autoimmune disease.

UI MeSH Term Description Entries
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D015375 Receptors, Interleukin-2 Receptors present on activated T-LYMPHOCYTES and B-LYMPHOCYTES that are specific for INTERLEUKIN-2 and play an important role in LYMPHOCYTE ACTIVATION. They are heterotrimeric proteins consisting of the INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT, the INTERLEUKIN-2 RECEPTOR BETA SUBUNIT, and the INTERLEUKIN RECEPTOR COMMON GAMMA-CHAIN. IL-2 Receptors,Interleukin-2 Receptor,Interleukin-2 Receptors,Receptors, IL-2,Receptors, T-Cell Growth Factor,T-Cell Growth Factor Receptors,IL-2 Receptor,IL2 Receptor,IL2 Receptors,Interleukin 2 Receptor,Receptor, TCGF,T-Cell Growth Factor Receptor,TCGF Receptor,TCGF Receptors,IL 2 Receptor,IL 2 Receptors,Interleukin 2 Receptors,Receptor, IL-2,Receptor, IL2,Receptor, Interleukin 2,Receptor, Interleukin-2,Receptors, IL 2,Receptors, IL2,Receptors, Interleukin 2,Receptors, T Cell Growth Factor,Receptors, TCGF,T Cell Growth Factor Receptor,T Cell Growth Factor Receptors
D016693 Receptors, Antigen, T-Cell, alpha-beta T-cell receptors composed of CD3-associated alpha and beta polypeptide chains and expressed primarily in CD4+ or CD8+ T-cells. Unlike immunoglobulins, the alpha-beta T-cell receptors recognize antigens only when presented in association with major histocompatibility (MHC) molecules. Antigen Receptors, T-Cell, alpha-beta,T-Cell Receptors alpha-Chain,T-Cell Receptors beta-Chain,T-Cell Receptors, alpha-beta,TcR alpha-beta,Antigen T Cell Receptor, alpha Chain,Antigen T Cell Receptor, beta Chain,Receptors, Antigen, T Cell, alpha beta,T Cell Receptors, alpha beta,T-Cell Receptor alpha-Chain,T-Cell Receptor beta-Chain,T-Cell Receptor, alpha-beta,T Cell Receptor alpha Chain,T Cell Receptor beta Chain,T Cell Receptor, alpha beta,T Cell Receptors alpha Chain,T Cell Receptors beta Chain,TcR alpha beta,alpha-Chain, T-Cell Receptor,alpha-Chain, T-Cell Receptors,alpha-beta T-Cell Receptor,alpha-beta T-Cell Receptors,alpha-beta, TcR,beta-Chain, T-Cell Receptor,beta-Chain, T-Cell Receptors
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

L Van Parijs, and A Biuckians, and A Ibragimov, and F W Alt, and D M Willerford, and A K Abbas
November 2005, Journal of immunology (Baltimore, Md. : 1950),
L Van Parijs, and A Biuckians, and A Ibragimov, and F W Alt, and D M Willerford, and A K Abbas
December 1991, International immunology,
L Van Parijs, and A Biuckians, and A Ibragimov, and F W Alt, and D M Willerford, and A K Abbas
September 1992, Immunology,
L Van Parijs, and A Biuckians, and A Ibragimov, and F W Alt, and D M Willerford, and A K Abbas
January 1996, Archivum immunologiae et therapiae experimentalis,
L Van Parijs, and A Biuckians, and A Ibragimov, and F W Alt, and D M Willerford, and A K Abbas
April 2007, Journal of immunology (Baltimore, Md. : 1950),
L Van Parijs, and A Biuckians, and A Ibragimov, and F W Alt, and D M Willerford, and A K Abbas
February 2024, Cytotherapy,
L Van Parijs, and A Biuckians, and A Ibragimov, and F W Alt, and D M Willerford, and A K Abbas
July 2019, Journal of immunology (Baltimore, Md. : 1950),
L Van Parijs, and A Biuckians, and A Ibragimov, and F W Alt, and D M Willerford, and A K Abbas
October 1991, Acta neurologica,
L Van Parijs, and A Biuckians, and A Ibragimov, and F W Alt, and D M Willerford, and A K Abbas
April 1992, Immunology,
L Van Parijs, and A Biuckians, and A Ibragimov, and F W Alt, and D M Willerford, and A K Abbas
August 2007, Folia morphologica,
Copied contents to your clipboard!